

**DSM Pharmaceutical Products**

45 Waterview Blvd  
Parsippany, NJ 07054-1298

**November 2, 2006****DSM Biologics and UMN Pharma Inc. Sign a Biopharmaceutical Manufacturing Agreement based on the PER.C6<sup>®</sup> Manufacturing Platform**

Parsippany, November 2, 2006

DSM Biologics (headquartered in Parsippany, NJ) and UMN Pharma, Inc. (headquartered in Akita, Japan) have signed a Biopharmaceutical Manufacturing Agreement based on the PER.C6<sup>®</sup> Manufacturing Platform. Under the terms of the Agreement DSM Biologics will provide UMN Pharma with (a) full process development services, (b) full analytical development services and (c) cGMP manufacturing batches for UMN Pharma's UMN-03 fusion protein. UMN Pharma develops the UMN-03 fusion protein for the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.

The services will be provided out of DSM Biologics' FDA-approved manufacturing facility in Groningen. The Agreement follows the License Agreement that was signed in March this year between UMN Pharma, DSM Biologics and Crucell.

Both parties are very pleased with the results of the collaboration to date. "The Agreement builds further on the PER.C6<sup>®</sup> License Agreement that is in place between UMN Pharma, DSM Biologics and Crucell. We gladly entrust DSM Biologics with the execution of this Manufacturing Agreement that is crucial for the success of our UMN-03 fusion protein" says Yasunari Kashihara, President & CEO of UMN Pharma, Inc.

"DSM Biologics is very happy to be involved in this exciting project. The agreement is a further example of the broad use of the PER.C6<sup>®</sup> manufacturing platform. It is also a clear recognition of the value that DSM Biologics and the PER.C6<sup>®</sup> manufacturing platform are expected to bring to UMN Pharma, an important client for DSM Biologics" says Terry Novak, Business Director and Chief Marketing Officer for DSM Biologics.

**About DSM Biologics**

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6<sup>®</sup> human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics' FDA-approved facility in Groningen, the Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6<sup>®</sup>, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6<sup>®</sup> human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. DSM Biologics is being represented

in Japan by Asahi Glass & Co., Ltd. For more information, please visit [www.dsmbiologics.com](http://www.dsmbiologics.com).

## About UMN Pharma

UMN Pharma, a pharmaceutical company, is dedicated to developing innovative disease preventives and therapeutics to satisfy unmet medical needs. UMN leverages extensive pharmaceutical industry experience to generate time-efficient, focused development plans followed by rapid preclinical and clinical development to meet both Japanese and international regulatory specifications. UMN has a diverse pipeline of novel small molecule and protein drug candidates targeted to cancer, diabetes and other major therapeutic markets. Four products are currently in preclinical development with the first clinical study scheduled for early 2007. UMN anticipates that four products will be in the clinical stage within a two-year timeframe. For more information, please visit [www.umnpharma.com](http://www.umnpharma.com).

## For more information:

### DSM Pharmaceutical Products

Terry Novak  
Chief Marketing Officer  
973-257-8471  
[Terry.Novak@dsm.com](mailto:Terry.Novak@dsm.com)

### DSM Biologics

Brad Carlson  
Vice President, Marketing, Sales & NBD  
Tel. +1 (585) 624-3844  
[Brad.Carlson@dsm.com](mailto:Brad.Carlson@dsm.com)

### DSM Biologics

Marcel Lubben  
Manager, New Business Development  
Europe & Asia  
+31 46 47 73343  
[Marcel-m.lubben@dsm.com](mailto:Marcel-m.lubben@dsm.com)

### UMN Pharma, Inc.

Yasunari Kashihara  
President & CEO  
+81 (3) 5728-5420  
[ykashihara@umnpharma.com](mailto:ykashihara@umnpharma.com)